A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

Lydia R. Meador, Sarah A. Kessans, Jacquelyn Kilbourne, Karen Kibler, Giuseppe Pantaleo, Mariano Esteban Roderiguez, Joseph Blattman, Bertram Jacobs, Tsafrir Leket-Mor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.

Original languageEnglish (US)
Pages (from-to)242-256
Number of pages15
JournalVirology
Volume507
DOIs
StatePublished - Jul 1 2017

Fingerprint

Vaccinia virus
Virion
HIV-1
Epitopes
T-Lymphocytes
Plant Viruses
AIDS Vaccines
Membranes
Antibody Formation
Immunization
Immunoglobulin G
Clinical Trials
Proteins

Keywords

  • Electron microscopy
  • HIV-1
  • Live vector vaccines
  • Prime/boost
  • Subunit vaccines
  • Tobacco mosaic virus
  • Vaccinia virus
  • Virus-like particles

ASJC Scopus subject areas

  • Virology

Cite this

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. / Meador, Lydia R.; Kessans, Sarah A.; Kilbourne, Jacquelyn; Kibler, Karen; Pantaleo, Giuseppe; Roderiguez, Mariano Esteban; Blattman, Joseph; Jacobs, Bertram; Leket-Mor, Tsafrir.

In: Virology, Vol. 507, 01.07.2017, p. 242-256.

Research output: Contribution to journalArticle

Meador, Lydia R. ; Kessans, Sarah A. ; Kilbourne, Jacquelyn ; Kibler, Karen ; Pantaleo, Giuseppe ; Roderiguez, Mariano Esteban ; Blattman, Joseph ; Jacobs, Bertram ; Leket-Mor, Tsafrir. / A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. In: Virology. 2017 ; Vol. 507. pp. 242-256.
@article{6ceef2025e874b50939ab8ca7f76bb8c,
title = "A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles",
abstract = "Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7{\%} of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.",
keywords = "Electron microscopy, HIV-1, Live vector vaccines, Prime/boost, Subunit vaccines, Tobacco mosaic virus, Vaccinia virus, Virus-like particles",
author = "Meador, {Lydia R.} and Kessans, {Sarah A.} and Jacquelyn Kilbourne and Karen Kibler and Giuseppe Pantaleo and Roderiguez, {Mariano Esteban} and Joseph Blattman and Bertram Jacobs and Tsafrir Leket-Mor",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.virol.2017.04.008",
language = "English (US)",
volume = "507",
pages = "242--256",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

AU - Meador, Lydia R.

AU - Kessans, Sarah A.

AU - Kilbourne, Jacquelyn

AU - Kibler, Karen

AU - Pantaleo, Giuseppe

AU - Roderiguez, Mariano Esteban

AU - Blattman, Joseph

AU - Jacobs, Bertram

AU - Leket-Mor, Tsafrir

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.

AB - Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and plant-produced HIV-1 virus-like particles (VLPs). Both components contained the full-length Gag and a membrane anchored truncated gp41 presenting the membrane proximal external region with its conserved broadly neutralizing epitopes in the pre-fusion conformation. We tested different prime/boost combinations of these components in mice and showed that the group primed with NYVAC-KC and boosted with both the viral vectors and plant-produced VLPs have the most robust Gag-specific CD8 T cell responses, at 12.7% of CD8 T cells expressing IFN-γ in response to stimulation with five Gag epitopes. The same immunization group elicited the best systemic and mucosal antibody responses to Gag and dgp41 with a bias towards IgG1.

KW - Electron microscopy

KW - HIV-1

KW - Live vector vaccines

KW - Prime/boost

KW - Subunit vaccines

KW - Tobacco mosaic virus

KW - Vaccinia virus

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=85018365502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018365502&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2017.04.008

DO - 10.1016/j.virol.2017.04.008

M3 - Article

VL - 507

SP - 242

EP - 256

JO - Virology

JF - Virology

SN - 0042-6822

ER -